# Sentinel Lymph Node Mapping in Thyroid Cancer: A Patient's Guide to What It Is, How It Works, and What the Research Shows This patient-friendly article explains how sentinel lymph node (SLN) mapping—a minimally-invasive technique already widely used in melanoma and breast cancer—is being applied to thyroid cancer, particularly papillary thyroid carcinoma (the most common type). For patients facing thyroid cancer surgery, this procedure helps doctors determine whether cancer has spread to lymph nodes in the neck, potentially sparing them from unnecessary removal of healthy lymph nodes. The original review article examines four main detection techniques (blue dye, radioactive tracer lymphoscintigraphy, combinations of these, and newer approaches like SPECT/CT and nanocarbon), analyzes data from more than 40 published studies, and discusses the procedure's detection rates, benefits, and current limitations. # Sentinel Lymph Node Mapping in Thyroid Cancer: A Patient's Guide to What It Is, How It Works, and What the Research Shows ## Table of Contents - Key Points - What Is the Sentinel Lymph Node (and Why Does It Matter)? - Understanding Thyroid Cancer: The Basics - How Thyroid Cancer Spreads to Lymph Nodes - Traditional Treatment: Neck Node Dissection and Its Risks - How Sentinel Lymph Node Mapping Works: The Four Main Techniques - What Do the Studies Show? Key Findings at a Glance - What Does This Mean for Patients? - Study Limitations: What We Still Don't Know - Recommendations and Takeaways for Patients - Frequently Asked Questions - Source Information ## Key Points - SLN mapping is a minimally invasive way to stage papillary thyroid cancer and identify the first lymph node draining the tumor. - Ultrasound misses hidden lymph node metastases in up to 30% of thyroid cancer patients, so SLN mapping can improve staging. - A negative sentinel node accurately predicts absence of cancer in other regional nodes, potentially avoiding unnecessary neck dissection. - In studies, combined lymphoscintigraphy plus blue dye showed the most consistent sentinel node detection, at 98–100%. - The technique's success depends heavily on surgeon experience; patients should seek care at centers with expertise in SLN mapping. ## What Is the Sentinel Lymph Node (and Why Does It Matter)? The story of the sentinel lymph node begins more than 370 years ago. In 1653, the term **“lymphatic”** was coined by Thomas Bartholin, and since then, anatomists and physicians have worked to understand this complex system and its role in how cancer spreads through the body. In the 1930s, the anatomist J.H. Gray made a breakthrough observation. By injecting colloidal thorium dioxide into surgical wounds, he saw that lymphatic pathways formed connections—called anastomoses—through which lymph fluid could be carried into different regional lymph nodes. His conclusion was simple but profound: the lymph nodes that drain a primary tumor are the first and most likely places where cancer will spread. In the 1950s, Weinberg began using blue dye during operations for gastric (stomach) and lung cancer. His goal was to highlight the "primary nodes" draining from the tumor by turning them blue, making them easy to see. Just minutes after injection, the dye stained the lymph vessels and lymph nodes. This had a direct and immediate benefit: surgeons could avoid unnecessary node dissections. Over the next two decades, researchers refined the technique. From the 1960s, attention shifted to testicular and penile cancers, where lymphography (imaging of the lymphatic system) helped clarify how drainage from a tumor goes to a specific group of lymph nodes. Between 1965 and 1968, R.M. Cabañas performed an impressive 250 lymphograms of various tumors—including penile, testicular, breast, melanoma, anal, and rectal cancers—for his thesis in Paraguay. In 1977, he presented his findings on penile carcinoma, officially introducing the term **"sentinel lymph node" (SLN)**. He concluded that the SLN's status could determine whether a complete lymph node dissection was needed. The field took a major leap forward when Morton and colleagues published the first clinical report on SLN surgery in 223 melanoma patients in 1992. Using isosulphan blue dye, they demonstrated that a limited number of lymph nodes receiving drainage from a tumor could be identified and removed for testing. At the "1st International Congress on the Sentinel Node in Diagnosis and Treatment of Cancer" in 1999, the SLN was formally defined as **the first lymph node draining the lymphatic flow from a primary cancer**. Since then, SLN mapping has rapidly become a standard diagnostic method for many solid tumors, including melanoma, vulvar carcinoma, penile cancer, colorectal cancer, and breast cancer. For the SLN concept to work, three conditions must be met: 1. There must be an ordered and expected pathway of lymphatic drainage from the tumor site to the regional lymph nodes. 1. Tumor cells must move sequentially through the lymphatics to a primary lymph node group. 1. The SLN must act as a filter, trapping tumor cells from the afferent lymph flow. The SLN procedure is a minimally-invasive diagnostic technique that carefully checks for the presence of regional lymph node metastases (cancer spread). A negative SLN accurately predicts the absence of metastases in the other regional nodes, thus avoiding unnecessary node dissection. For thyroid cancer specifically, the first SLN study was reported in 1998 by Kelemen et al. They studied 17 patients with thyroid cancer using 1% Patent Blue V dye. The **detection rate (DR)**—meaning the percentage of patients in whom the SLN was successfully found—was 88%, and the SLN was positive for metastases in 42% of patients. This pioneering work laid the foundation for dozens of subsequent studies. ## Understanding Thyroid Cancer: The Basics Thyroid nodules are extremely common in the general population. Their prevalence ranges from as low as 4–5% when detected by physical examination to 50–67% when detected by ultrasound or at autopsy. The good news: only about 5% of these nodules are malignant (cancerous). About 80% are colloid nodules, cysts, or thyroiditis (inflammation-related) nodes, and 10–15% are benign follicular neoplasms. **Thyroid carcinoma (TC)** is the most common endocrine cancer overall. It ranks as the 11th most frequent cancer of all cancers, but it is the 5th most common cancer in women. Women have a global incidence rate three to four times higher than men. The highest thyroid cancer rates have been observed in North America, Australia, New Zealand, East Asia, and Southern Europe. The thyroid gland contains two main cell types: follicular cells and C cells (also called parafollicular cells). Understanding this distinction is important because it determines the type of cancer: - **Differentiated thyroid cancers (DTC)**—including papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), and anaplastic thyroid cancer (ATC)—arise from follicular cells. Poorly differentiated thyroid cancers also originate here. - **Medullary thyroid carcinoma (MTC)** arises from C cells. Over 90% of thyroid cancer cases are well-differentiated DTCs. Of these, PTC accounts for about 85% and FTC for about 10–15%. Several risk factors increase the chance of developing DTC: - Exposure to radiation in childhood - Age - Female gender - Family history - Hashimoto's thyroiditis (an autoimmune condition) The age at radiation exposure matters greatly. In the first decade after the Chernobyl accident, some regions of Belarus saw a **100-fold rise in thyroid cancer** among people who were under age 15 at the time of exposure. Additionally, epidemiological studies show that first-degree relatives (parents, siblings, children) of people with thyroid cancer have a four- to ten-fold increased risk of developing DTC themselves. Papillary thyroid cancer is classically characterized by its papillary (finger-like) appearance and distinctive nuclear features. More than 10 histological variants have been documented. It is generally considered an indolent (slow-growing) tumor, with a 30-year survival rate of over 90%. However, PTC is a "lymphophilic" cancer—it has a strong tendency to spread to lymph nodes. Cervical (neck) lymph node metastases are frequent and increase the probability of the disease persisting or recurring in the neck region. Tumor size, extracapsular invasion (spread beyond the thyroid capsule), and multifocality (multiple tumor foci) are all factors associated with lymph node metastases. Distant metastases (spread to other organs) are a strong predictor of poor prognosis. Among patients who die from thyroid cancer, 43–90% have distant disease. Fortunately, hematogenous (blood-borne) distant metastasis is rare: only 1–2% of PTC patients have metastases outside the neck or mediastinum at the time of diagnosis, most commonly in the lungs and bones. Follicular thyroid cancer (FTC) accounts for 10–15% of DTCs. Unlike PTC, which is typically diagnosed by cytology (cell examination), FTC is usually diagnosed at histology (tissue examination after surgery). FTC is more aggressive than the typically indolent PTC. Distant metastases, mainly in the lungs and bone, occur in 3–30% of cases, while lymph node metastases are rare. ## How Thyroid Cancer Spreads to Lymph Nodes The lymphatic drainage system of the thyroid is a complex network. In PTC, the **central neck compartment** is the most frequently involved site of metastatic disease, although metastases in the lateral (side) and mediastinal (chest) compartments are also common. The lymphatic channels of the thyroid capsule cross-communicate with the isthmus (the bridge of tissue connecting the two thyroid lobes) and the opposite lobe. As a result, the direction of lymphatic fluid draining through intra-thyroid capillaries is not always predictable. The drainage patterns follow some general rules worth understanding: - The isthmus and the medial superior portion of the thyroid lobes usually drain through superior lymphatic vessels that rise in front of the larynx (voice box) and reach the subdigastric lymph nodes of the internal jugular chain. - The media inferior lymphatics terminate in the pretracheal lymph nodes (in front of the windpipe). - The lateral lymphatics drain to the superior lymph nodes of the internal jugular vein. The data on lymph node involvement in PTC is striking: - Between **15% and 50%** of PTCs have cervical lymph node metastases at diagnosis, but microscopic metastases are found in up to **80%** of cases. The wide range reflects the different extents of neck node dissection performed in different studies. - Metastases occur in the central compartment (level VI)—including the pretracheal, paratracheal, perithyroidal, and precricoid nodes—in approximately **90%** of cases. - Metastases in the Delphian lymph node (a node in front of the thyroid cartilage) are associated with latero-cervical (side-neck) metastases in up to **33%** of cases. - The lateral compartment is involved in between **51% and 100%** of cases in different series. The lower jugular compartment (level IV) is the second most commonly affected site, followed by the middle (level III) and upper jugular (level II) compartments. - Less common are level V and VII metastases, occurring in 2–15% of cases. - The contralateral (opposite side) lymph nodes are involved in up to **18–25%** of PTC cases. - Lateral skip metastases (where cancer bypasses the central compartment and goes directly to the lateral nodes) are found in up to **20%** of cases. In PTCs smaller than 10 millimeters, lymph node metastases are rare and, when they occur, are generally confined to the central compartment. Lymph node involvement is an unfavorable prognostic factor, particularly for disease-free survival (the length of time a patient lives without cancer recurrence), rather than for overall survival. Other principal adverse prognostic factors include male gender, age 55 years or older, tumor size larger than 3 centimeters, and extra-nodal extension (cancer spreading beyond the lymph node capsule). ## Traditional Treatment: Neck Node Dissection and Its Risks Because the thyroid's lymphatic drainage network is so complicated, the direction of tumor lymphatic drainage is not always predictable during surgery. Traditional treatment for PTC with positive lymph nodes requires both total thyroidectomy (removal of the entire thyroid) and node dissection (surgical removal of lymph nodes). The management of patients whose preoperative evaluation shows no lymph node involvement (called **N0 status**) is a controversial issue. Given the high rate (up to 80%) of occult (hidden) micro-metastases and the resulting higher rate of locoregional persistence or recurrence in PTC, treatment approaches range from "node picking" (removing only suspicious nodes) to ipsilateral (one side) or radical central node dissection (CND). This matters because **central neck dissection carries significant risks**. It can damage the recurrent laryngeal nerves (RLN), which control the vocal cords, and it increases rates of hypoparathyroidism (underactive parathyroid glands, which control calcium levels). This can lead to overtreatment in patients who actually have negative lymph nodes. While some argue that the risks of CND are no greater than those of total thyroidectomy alone—especially when performed by an experienced surgeon—there is much debate about this. A 2009 review of seventeen studies involving 1,929 patients reported the following complication rates after CND: - Transient hypocalcaemia (temporary low calcium): **3.6–60.0%** - Permanent hypocalcaemia: **0.0–14.4%** - Temporary recurrent laryngeal nerve injury: **0.0–25.0%** - Permanent recurrent laryngeal nerve injury: **0.0–11.5%** Current guidelines from the American Thyroid Association (ATA) recommend **therapeutic** CND (removal of affected nodes) only for patients with preoperatively confirmed central lymph node metastases. **Prophylactic** CND (preventive removal) is recommended for patients without preoperative central lymph node metastases (cN0) but with advanced primary tumors (T3 or T4) or preoperative lateral lymph node metastases (cN1b), or when knowing the lymph node status is needed to plan further treatment steps. For patients with cN0 status and T1 or T2 tumors, prophylactic CND is not recommended. It's important to note how patients are classified as cN0: through clinical examination and high-resolution neck ultrasonography (hrUS). However, hrUS can produce **false-negative results in up to 30% of patients**, because it simply cannot detect occult (hidden) lymph node metastases. This is precisely where sentinel lymph node mapping becomes valuable. ## How Sentinel Lymph Node Mapping Works: The Four Main Techniques The SLN procedure in PTC is an intraoperative (during-surgery) method of staging. It is used to find metastatic lymph nodes "in and outside" the central compartment in cN0 patients, and to identify patients who might benefit from lymph node dissection instead of prophylactic CND. Remember: the SLN is the first regional lymph node (or group of nodes) affected by metastases from a primary tumor. A negative SLN accurately predicts the lack of metastases in the other lymph nodes. Four SLN identification techniques are currently used: 1. The selective vital-dye (VD) method 1. 99mTc-nanocolloid planar lymphoscintigraphy with intraoperative use of a hand-held gamma probe (LS) 1. A combination of LS and VD (LS + VD) 1. 99mTc-nanocolloid planar lymphoscintigraphy with preoperative SPECT–CT and intraoperative use of a hand-held gamma probe (LS-SPECT/CT) ### Technique 1: The Vital Dye (Blue Dye) Method The most frequently used blue dyes are isosulphan blue, patent blue violet (V), sodium blue, and methylene blue. A literature search of PubMed (conducted by the review authors) found **33 papers** on SLN in thyroid cancer using the blue dye method: 6 using isosulphan blue, 8 using patent blue V, and 19 using methylene blue. Among the largest studies: - **Cunningham et al. (2010)** examined 211 PTC patients using 1% isosulphan blue, achieving a detection rate (DR) of **91%**. - **Rubello et al. (2006)** used patent blue V in 153 PTC cases, with a DR of **69%**. - **Markovic et al. (2020)** used methylene blue in 153 PTC patients, with a DR of **91.8%**. - **Santrac et al.** used methylene blue in 20 medullary thyroid carcinoma (MTC) patients, achieving a DR of **100%**, with 10% positive for metastasis. - **Wang et al.** described using indocyanine green (ICG) combined with methylene blue to detect SLNs in 45 micro-PTC patients. This approach required a longer operative time but resulted in a lower rate of hypoparathyroidism. The authors concluded that combining ICG with methylene blue is feasible, safe, and clinically significant for protecting the parathyroid glands. - **Moskalenko et al.** evaluated 187 patients using (for the first time) a 1% toluidine blue aqueous solution, achieving a DR of **97.6%**, and found it no less accurate than other blue dyes. Here's how the blue dye procedure works in practice: At surgery, the vital blue dye is injected intra- or peri-tumorally (inside or around the tumor), generally using a tuberculin syringe. The authors strongly recommend **not mobilizing (moving) the thyroid before injection** to ensure the lymphatic drainage remains intact. The blue dye can usually be seen moving through the lymphatics to the SLN within seconds, though sometimes it takes 1–2 minutes. The blue-colored lymph nodes are then excised (removed) very cautiously to avoid removing the parathyroid glands, which can also accidentally turn blue. After dissection, the SLNs are sent to pathology for frozen section analysis (rapid microscopic examination during surgery). The main limitations of the vital dye method include: 1. Potential disruption of the lymphatics draining the tumor 1. Difficulty identifying SLNs located outside the central compartment 1. The risk of removing blue-stained parathyroid glands 1. The procedure is laborious and requires experience ### Technique 2: Lymphoscintigraphy with Gamma Probe (LS) The PubMed search found **14 papers** on SLN in thyroid cancer using the LS method. This technique was first described by Rettenbacher et al. and was introduced to overcome some of the drawbacks of the vital dye method. Key study results: - **Carcoforo et al.** assessed 345 PTC patients and detected SLNs in **100%** of them, with 22.6% positive for metastases. - **Kim et al.** evaluated 16 MTC patients and detected SLNs by radioisotope in **87.5%** of cases. The LS procedure works like this: Under ultrasound guidance, 99mTc-albumin nanocolloid particles are injected peri- or intra-tumorally. This radioactive tracer travels through the lymphatics, allowing the lymph vessels and SLN to be visualized on imaging. The skin projection of the SLN is then validated by external counting with a hand-held collimated gamma probe and marked with a permanent marker. After a varying time interval (2–24 hours), the patient is taken to the operating room. Following thyroidectomy (to avoid interference from the radioactivity of the primary tumor), the central and lateral node compartments are scanned with the hand-held gamma probe. The radioactive lymph nodes are identified, and the SLN is selectively removed. The radioactivity of the lymphatic bed is monitored to verify that the SLN dissection is complete, and the node is sent for pathology. According to the authors, SLN detection remains feasible up to 24 hours post-injection. The LS method offers important advantages over the blue dye method: 1. The preoperative ultrasound-guided injection of radioactive particles removes the risk of damaging lymphatic vessels during surgery. 1. The SLN can be localized both in and outside the central compartment. 1. There is no radioactive particle uptake by the parathyroid glands. ### Technique 3: The Combination (LS + VD) The combination of lymphoscintigraphy and blue dye was first described in 6 PTC patients by Catarci et al. Two hours before surgery, patients received an intra-tumoral injection of 99mTc-labeled colloidal albumin to visualize the SLN at lymphoscintigraphy. At surgery, Patent Blue V (2.5%) was injected intra-tumorally, and the blue-stained SLN was localized using a hand-held gamma probe. The SLN was identified in **all 6 cases**, and the authors concluded that these two techniques have a complementary role. Other researchers who have evaluated this combination include Lee et al., Huang et al., Assadi et al., and Gelmini et al. ### Technique 4: LS-SPECT/CT With this technique, the SLN is localized using a combination of 99mTc-nanocolloid planar lymphoscintigraphy, preoperative SPECT/CT imaging (a 3D imaging technique), and intraoperative use of a hand-held gamma probe. This hybrid approach provides detailed anatomical information about the SLN's location. ### Newer Techniques on the Horizon Nanotechnology has opened new possibilities. **Nanocarbons (CN)** have been used as lymph node tracers. These particles have an average diameter of 150 nanometers. When injected peritumorally, they are rapidly taken up by macrophages (immune cells), then enter the lymphatics and accumulate in the lymph nodes, staining them black. In a 2012 study, 100 micro-PTC patients received a peritumorally injection of CN suspension. Within a few minutes, the lymphatic flow and the black-stained SLN in the central compartment were identified. The detection rate was **93.3%**, with **61.1%** of detected SLNs positive for metastases. Zhang et al. also examined the feasibility of combining ICG and CN injection to localize the SLN in 40 micro-PTC patients. Looking to the future, a particularly promising approach is **68Ga-tilmanocept PET/CT**. De Vries et al. proposed a clinical protocol using 68Ga-tilmanocept PET-CT combined with ICG-99mTc-nanocolloid in ten patients with DTC and MTC. In this protocol, patients receive a sequential ultrasound-guided injection of 68Ga-tilmanocept and ICG-99mTc-nanocolloid, followed 15–60 minutes later by 68Ga-tilmanocept PET/CT. The next day, the SLN location is defined preoperatively using a hand-held gamma probe and marked on the skin. At surgery, the SLN is excised using the PET/CT images, skin markings, gamma probe, and a fluorescence camera. According to the authors, this new imaging modality reduces the "shine-through effect" seen with the standard LS method, where radioactivity from the injection site near the tumor interferes with SLN detection. The PET/CT better localizes the SLN even when it is close to the tumor. ## What Do the Studies Show? Key Findings at a Glance To evaluate the "state of the art" of the SLN method in thyroid cancer, the authors' surgical team conducted a comprehensive review in 2016. They looked at **41 studies** on SLN detection in thyroid cancer: - **26 studies** used the vital dye technique (patient numbers ranging from 9 to 300) - **12 studies** used the lymphoscintigraphy technique (1 to 374 patients) - **3 studies** used the combination of LS + VD (6 to 45 patients) The results showed considerable variation between techniques: - **SLN visualization rates:** The SLN was successfully visualized in 0–100% of cases with the vital dye method, 64–100% with the LS method, and 98–100% with the combined LS + VD method. - **Metastasis positivity rates:** The SLN was positive for metastases in 14–86% of cases with the vital dye method, 16–100% with the LS method, and 50–67% with the combined method. The authors concluded that the SLN technique is feasible in thyroid cancer, but the wide ranges in these numbers highlight the heterogeneity (variability) of the techniques and study populations. The detection of the SLN in thyroid carcinoma has been described in many studies, but the role of the procedure—including its indications, results, advantages, and limits—is still debated. ## What Does This Mean for Patients? For patients with papillary thyroid cancer, particularly those classified as cN0 (no evidence of lymph node spread on ultrasound), SLN mapping offers several potential benefits: - **More accurate staging:** SLN mapping can detect metastatic lymph nodes "in and outside" the central neck compartment that ultrasound might miss. Remember, hrUS has a false-negative rate of up to 30%. - **Avoiding unnecessary surgery:** A negative SLN accurately predicts the absence of metastases in other regional lymph nodes, meaning patients with negative SLNs can avoid prophylactic central neck dissection and its associated risks—including damage to the recurrent laryngeal nerves and hypoparathyroidism. - **Targeted treatment:** For patients with a positive SLN, the procedure identifies who might benefit from a formal lymph node dissection instead of a "blind" prophylactic dissection. This allows surgeons to focus the dissection on the compartments actually at risk. - **Parathyroid protection:** Some techniques, such as combining ICG with methylene blue, may offer better protection of the parathyroid glands during surgery. ## Study Limitations: What We Still Don't Know It is important to understand the limitations of this review and of SLN mapping in thyroid cancer in general: - **Heterogeneous techniques:** The studies used different dyes, different radioactive tracers, different injection methods, and different time intervals between injection and surgery. This makes direct comparisons difficult. - **Wide variation in results:** Detection rates ranged from 0% to 100% across studies, and positivity rates ranged from 14% to 100%. This suggests that the technique's success is highly dependent on the surgeon's experience and the specific technique used. - **Small patient numbers:** Many studies included fewer than 50 patients, with some as few as one patient. The largest study had 374 patients, which is modest compared to SLN studies in breast cancer or melanoma. - **Technique-specific drawbacks:** The blue dye method risks staining the parathyroid glands and damaging lymphatics; the LS method suffers from the "shine-through" effect where radioactivity near the tumor interferes with detection. - **Ongoing debate:** The role of SLN in thyroid cancer—with its indications, results, advantages, and limits—is still a subject of debate in the medical community. - **No long-term outcome data:** This review focuses on detection rates and SLN positivity, not on long-term patient outcomes such as recurrence rates or survival. Whether SLN-guided surgery improves these outcomes remains to be proven. ## Recommendations and Takeaways for Patients Based on this review, here are the key takeaways for patients who may be considering or discussing SLN mapping with their care team: 1. **Ask about SLN mapping if you have a confirmed or suspected PTC diagnosis** with no evidence of lymph node spread (cN0). The procedure may help you avoid a more extensive central neck dissection and its risks. 1. **Understand that technique matters.** The combined LS + VD approach showed the most consistent visualization rates (98–100%) in the review, although the newer SPECT/CT and nanocarbon techniques also show promise. Ask your surgeon which technique they use and how experienced they are with it. 1. **Know the risks of the alternatives.** If you have a prophylactic central neck dissection instead of SLN mapping, be aware that temporary low calcium affects 3.6–60% of patients, permanent low calcium affects up to 14.4%, and temporary vocal cord nerve injury affects up to 25%, according to the 2009 review of 1,929 patients. 1. **Remember that ultrasound is not perfect.** Up to 30% of patients with a "clean" ultrasound will actually have hidden lymph node metastases. SLN mapping can catch many of these. 1. **Stay informed about newer technologies.** Techniques like 68Ga-tilmanocept PET/CT and fluorescence-guided surgery with ICG are evolving rapidly and may offer even better detection with fewer side effects in the near future. 1. **Choose a high-volume center.** The success of SLN mapping depends heavily on surgical experience. Because the procedure is laborious and requires skill, patients should seek care at centers with demonstrated expertise in this technique. In summary, sentinel lymph node mapping is a valuable, minimally-invasive tool that is increasingly being applied to thyroid cancer surgery. It offers the possibility of more accurate staging, fewer unnecessary operations, and better protection of vital structures in the neck. While the optimal technique and its exact role are still evolving, the evidence to date supports its use in carefully selected patients with papillary thyroid carcinoma. ## Frequently Asked Questions ### What is sentinel lymph node (SLN) mapping for thyroid cancer? SLN mapping is a minimally invasive technique used during thyroid cancer surgery to find the first lymph node that drains fluid from the tumor. This sentinel node is removed and tested for cancer. If it is negative, other neck nodes are likely cancer-free, helping avoid removal of healthy lymph nodes. ### Who might be a candidate for sentinel lymph node mapping? The procedure is mainly for people with papillary thyroid cancer, the most common type, especially when ultrasound shows no lymph node spread, called cN0 status. Because ultrasound can miss hidden metastases in up to 30% of patients, SLN mapping can provide more accurate staging in these cases. ### How is sentinel lymph node mapping performed? During surgery, a blue dye, a radioactive tracer, or both are injected into or around the thyroid tumor. The tracer travels through lymphatic vessels to the sentinel node, which is then located using a gamma probe or by its blue color. The node is removed and examined under a microscope during the operation. ### What are the possible risks or side effects? SLN mapping itself is minimally invasive, but if the sentinel node is positive, a more extensive neck dissection may be needed. That surgery carries risks including temporary or permanent low calcium and injury to nerves controlling the vocal cords. Some blue dye methods can stain parathyroid glands, while radioactive tracer methods may have a 'shine-through' effect. ### How accurate is sentinel lymph node mapping in thyroid cancer? Accuracy varies widely by technique. In published studies, detection rates ranged from 0–100% with blue dye, 64–100% with lymphoscintigraphy, and 98–100% with the combined method. Sentinel node positivity for cancer ranged from 14–86% depending on the study and patient group. Success depends on surgeon experience and technique. ### Can SLN mapping help me avoid a full neck dissection? If your sentinel node is negative, it accurately predicts that other lymph nodes do not contain cancer, so a preventive central neck dissection can be avoided. If the sentinel node is positive, your surgeon may perform a formal lymph node dissection to remove affected nodes. SLN mapping helps target only the nodes that need removal. ### What should I ask my surgeon about sentinel lymph node mapping? Ask whether SLN mapping is appropriate for your type and stage of thyroid cancer, especially if you have no lymph node spread on ultrasound. Ask which technique they use, their experience with it, and whether it can help you avoid a central neck dissection. Also discuss the risks and benefits compared with standard surgery. ## Source Information This patient-friendly article is based on the following peer-reviewed research publication: - **Original title:** Sentinel lymph node mapping: current applications and future perspectives in thyroid carcinoma - **Authors:** Isabella Merante Boschin, Loris Bertazza, Carla Scaroni, Caterina Mian, and Maria Rosa Pelizzo - **Journal:** Frontiers in Medicine (Volume 10, Article 1231566) - **Publication date:** 24 October 2023 - **DOI:** 10.3389/fmed.2023.1231566 This article is an open-access publication distributed under the terms of the Creative Commons Attribution License (CC BY). It has been adapted into plain language for educational purposes. The original source contains full citations and references for all studies mentioned here. Always consult your physician for medical advice specific to your situation. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/sentinel-lymph-node-mapping-in-thyroid-cancer-a-patients-guide-to-what-it-is-how-it-works-and-what-the-research-shows